Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: Results of a systematic review

(2013) Herma H Fidder   WORLD JOURNAL OF GASTROENTEROLOGY

Anti-infliximab antibodies in inflammatory bowel disease

(2012) Lennard Y.W. Lee et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

(2010) S. Lichtiger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients

(2010) Jason M. Swoger et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

(2009) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

(2009) C. MA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT